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ABSTRACT: Since January 2017, there have been at least 1563 
suspected cases of Yellow Fever, 629 confirmed cases and 232 
confirmed deaths. Yellow fever is a viral hemorrhagic disease 
endemic to the tropical parts of Africa and South America. At 
the present time, it has presented a significant increase in its 
incidence in Brazil, with important repercussions and impacts 
on the public health. This review paper outlines the causes of 
yellow fever, as well as the disease epidemiology, progression, 
diagnosis, treatment and prevention. We conclude by reporting on 
the current epidemic in Brazil and future directions for research. 
Method: Data from Pubmed, SciELO, Medline and government 
sources concerning Yellow Fever were used, dating from 2002 to 
2018. In the collection of the data the following descriptors were 
used: Yellow-fever, Aedes, Arbovirus and Flavivirus.
Keywords: Yellow fever; Flavivirus; Flavivirus infections; Aedes; 
Hemorrhage.
RESUMO: Desde Janeiro de 2017, foram reportados 1563 casos 
suspeitos de Febre Amarela, sendo confirmados 629 casos, dos 
quais foram confirmadas 232 mortes devido a doença. A Febre 
Amarela é uma doença febril hemorrágica, sendo endêmica de 
regiões tropicais da África e América do Sul. Nos dias atuais, tem 
apresentado aumento significativo em sua incidência no Brasil, 
com repercussões e impactos importantes na saúde pública do 
país. Neste artigo são descritas as causas de Febre Amarela, bem 
como sua epidemiologia, progressão, os métodos diagnósticos, 
tratamento e prevenção da doença, de forma a promover 
atualização epidemiológica e direcionar futuras pesquisas na área. 
Método: Foram utilizados dados do Pubmed, SciELO, Medline e 
de fontes governamentais, referentes a Febre Amarela, que datam 
de 2002 à 2018. Na coleta do dados foram utilizados os seguintes 
descritores: Febre Amarela, Aedes, Arbovírus, Flavivirus.
Descritores: Febre amarela; Flavivirus; Infecções por arbovírus; 
Aedes; Hemorragia.
 
408
Ribeiro Junior MAF, et al. Yellow Fever: a review and the current epidemiological situation in Brazil.
INTRODUCTION
Epidemiology
Yellow fever is a mosquito-borne viral disease that is endemic to the tropical parts of Africa 
and South America. The viral hemorrhagic fever (VHF) is 
caused by approximately 70 positive single-stranded RNA 
viruses belonging to the Flaviviridae family. The yellow 
fever virus (YFV) are small (40 to 60nm), enveloped and 
icosahedral in shaped1,2. It is the E glycoprotein on the 
surface of the virus that is responsible for virion attachment, 
assembly, fusion and immunogenicity2.
Yellow fever continues to affect 180,000 people with 
roughly 78,000 deaths annually3. Approximately 1 billion 
people among 46 countries live within areas considered 
to be at risk for infection by YFV3. In South America, 
Argentina, Bolivia, Brazil, Colombia, Ecuador, Guyana, 
French Guyana, Paraguay, Peru, Suriname, Trinidad and 
Tobago and Venezuela are areas at risk of yellow fever2. 
Figure 1 provides a detailed look at the areas at risk for 
yellow fever in Brazil as of January 2017.
Figure 1. Areas at risk for yellow fever in Brazil. Accessed from Pan American Health Organization (PAHO)5
There are three cycles in the spread of yellow 
fever to humans; the sylvatic (jungle), intermediate and 
urban cycles. In the jungles of South America and Africa, 
the sylvatic phase involves the spread of YFV between 
non-human primates by several mosquito species (e.g. 
Haemogogus genera)1,2. Humans working in these jungle 
areas can be infected with the virus and allows the virus to 
move into the intermediate cycle. This phase occurs when 
the virus enters towns and villages bordering jungle areas. 
Here YFV is spread by infected, semidomestic species of 
mosquitos that feed on both monkey and human hosts. The 
urban cycle starts when YFV is introduced into areas of high 
population density. This phase is responsible for human 
epidemics of yellow fever; worse epidemics are linked 
to high-density populations with a significant number of 
unvaccinated people, as well as prolonged rainfall and 
temperature increases1,2,4. Transmission between humans 
occurs via inoculation by the Ae aegypti mosquito and it 
is not contagious between humans2. 
METHOD
This review was sourced from articles available 
from Pubmed, SciELO and Medline. Official data was 
obtained from government sources. The dating of the data 
ranged from 2002 to 2018.
Pathogenesis and clinical manifestations
Severe VHF has a fatality rate of 20-50% and is 
typically characterized by viremia, fever, liver dysfunction, 
renal damage, myocardial injury, hemorrhage and shock2. 
YFV causes these diseases by direct or indirect attack 
on the microvasculature, leading to increased vascular 
permeability and local hemorrhage6. The timeline of disease 
progression is as follows.
Period of infection
When an infected female mosquito is blood feeding, 
it inoculates roughly 1000 to 100,000 virus particles into the 
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host’s skin. At the site of inoculation, the virus replicates 
in the dendritic cells of the epidermis and spreads to the 
regional lymph nodes via lymphatic channels. From here, 
the virus can reach other organs via the lymphatic and 
circulatory systems7.
There is an incubation period of 3-6 days before 
the symptoms abruptly appear. Typically, the patient is 
febrile and experiences nausea, vomiting, malaise, myalgia, 
irritability and dizziness8. In severe cases, patients may 
also display Faget Sign, whereby there is an increase in 
temperature while pulse rate decreases2. During this period, 
the viral load is high enough to infect biting mosquitos, 
leading to further spread between humans.
Period of remission
Patients with mild disease typically recover without 
lasting complications; those with more severe disease can 
then enter a “period of remission”, where the fever and 
other symptoms subside rapidly for 24 hours. There is 
clearance of the virus from the patient’s circulation and 
patients have another chance of resolving the infection 
without any permanent sequelae2.
Period of intoxication
In approximately 20% of patients, the illness 
progresses to a more severe form, (period of intoxication)2. 
Patients report high fevers, abdominal pain, dehydration, 
prostration and vomiting. There are also symptoms 
according to the organ involved. In yellow fever, the liver 
is the primary target of the YFV2.
With liver dysfunction, a patient may develop 
coagulopathies that produce severe hemorrhage manifesting 
as petechiae, ecchymosis, epistaxis and hematemesis 
(gastrointestinal hemorrhage that is vomited up). Severe 
liver damage may also manifest in the patient as jaundice. 
On gross pathological examination of the liver, the lobular 
markings are destroyed, the liver size is normal or enlarged 
and appears icteric. Councilman bodies are hallmarks of 
fatal yellow fever infection2.
Renal failure and albuminuria has also been reported 
during the period of intoxication. On gross pathological 
examination there are enlarged, edematous kidneys with 
signs of acute tubular necrosis2.
Central nervous system symptoms may then occur 
during this stage of the disease as well and symptoms 
include seizures, coma and finally death roughly 8-10 days 
after infection2,9.
 
Diagnosis
A presumptive diagnosis of yellow fever is often 
based on the patient’s clinical features, places and dates 
of travel (if the patient is from a non-endemic region), 
activities, and epidemiologic history of the location where 
the presumed infection occurred10.
However, yellow fever is difficult to diagnose, 
especially during the early stages because in approximately 
90% of cases, the clinical condition is asymptomatic or 
oligosymptomatic11.
The clinical spectrum of yellow fever can range 
from asymptomatic infections to severe and fatal conditions 
as described previously. It is important to highlight that 
the disease expression is independent of the transmission 
context, whether urban or wild13. 
Timely diagnosis is essential for the management of 
yellow fever outbreak, as it allows public health workers to 
effectively prioritize vulnerable locations and populations 
and provide vaccination and vector control measures if 
deemed necessary14. The disease can be detected using 
serology; viral genome by polymerase chain reaction 
(PCR) in serum; virus isolation; or histopathology and 
immunocytochemistry15. However, these tests require 
highly trained laboratory staff and specialized equipment 
and materials, which may be a problem for some under-
resourced areas12. Laboratory diagnosis can be divided into 
specific and non-specific:
Specific laboratory diagnosis
Laboratory investigations are important and involve 
isolating the flavivirus in VERO cells or C6/36 clone. The 
virus is identified by complement fixation tests and indirect 
immunofluorescence, in addition to PCR11.
The diagnosis can be confirmed by detection of 
viral antigens and viral RNA, as well as serology with 
IgM capture in enzymatic assay in paired sera. A four-fold 
or greater increase in antibody levels measured by IgM 
ELISA or by hemagglutination inhibition test in paired 
sera indicates an acute or recent flavivirus infection in 
unvaccinated people11,16. In fatal cases, specific antigens 
are detected by immunohistochemistry in tissues, which 
should be collected within the first eight hours after death. 
The collected specimen should then be sent to the reference 
laboratories specific to where the cases occurred11.
The serology may have two samples. The first 
sample should be collected after the fifth day of symptoms 
and a second collected within 14 to 21 days of the initial 
collection. 
Test results are normally available 4 to 14 days after 
receiving the specimen. Reporting times for test results may 
be longer during summer months when domestic arbovirus 
activity increases. Receipt of a hard copy of the results takes 
at least 2 weeks after testing is completed10.
Non-specific laboratory diagnosis
Leukopenia ,  lymphocytosis  and marked 
thrombocytopenia are observed in the severe forms of 
yellow fever, without direct correlation with levels and 
bleeding. In asymptomatic and oligosymptomatic cases, 
blood count may be normal11. In severe cases, there may be 
marked leukocytosis, significantly high aminotransferases 
and change in coagulation factors, mainly prothrombin, 
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factor VIII and thromboplastin11,16. Both creatinine and 
urea levels can rise and their worsening correlates with 
deterioration of patient’s condition17. Urinalysis can show 
bilirubinuria, hematuria, and marked proteinuria, with 
values above 500 mg/100 mL of urine11.
Differential diagnoses
During epidemic outbreaks, it is relatively easy 
to diagnose yellow fever, since the existence of previous 
cases during the period increases clinical suspicion. 
During periods of no epidemic outbreaks, diagnosis can 
be problematic. Thus, a syndromic approach to diagnosis 
is often used11. Infectious diseases that should be included 
in the differential diagnoses include malaria, viral hepatitis, 
typhoid, hemorrhagic dengue and septicemia. Among non-
infectious causes, idiopathic thrombocytopenic purpura and 
poisoning, including venomous snake bites that produce 
hemorrhaging should be ruled out7,11.
The clinical history, epidemiological antecedents 
and early performance of laboratory exams are the main 
methods of diagnosis in the majority of yellow fever cases. 
Management and treatment
Care for the patient with yellow fever is mainly 
supportive as there is no specific antiviral therapy currently 
available15. Patients may benefit from intensive care but 
despite the assistance of modern hospitals the case fatality 
rate among patients with yellow fever remains 35%, 
suggesting that intensive care makes little difference to 
outcome of this disease18,19.
Nowadays, it is recommended that the patient should 
be managed in an intensive care unit (ICU) and closely 
monitored for disseminated intravascular coagulation 
(DIC), hemorrhage, kidney, and liver dysfunction. 
Coagulopathy is managed with fresh frozen plasma, and 
renal failure may require dialysis20.
According to an article publish in 2018 by Song et 
al.21, one way to approach a patient with liver dysfunction 
is a liver transplantation (LT). For the first time, a LT was 
performed to treat a patient with severe YF. This new 
approach, although it may represent a paradigm shift in the 
management, LT could improve survival of some patients 
who would certainly otherwise die21.
In past years, research has been conducted on the 
use of passive antibodies, interferons, immunomodulators 
and other drugs like tiazofurin, orotidine 5-monophosphate 
decarboxylase inhibitors, isoquinolone alkaloid drugs, 
6-azauridine and related compounds, triaryl pyrazoline and 
iminocyclitol compounds with a deoxynojirimycin22. In the 
case of interferon and passive administration of antibodies, 
this approach may prevent disease only if given in a very 
short window after infection23. Research on the treatments 
mentioned did not demonstrate effectiveness on humans19.
In studies in nonhuman primates, ribavirin treatment 
was not effective in prolonging survival. However, in an 
animal model, ribavirin initiated at a high loading dose (80 
mg/kg) followed by daily doses of 40 mg/kg and started 
up to 120 hours after infection showed reduced mortality 
and hepatocellular dysfunction in hamsters23.
According to Freitas et al.24, another drug that has 
been shown efficacy as treatment for YF is Sofosbuvir. 
Other Flaviviruses, such Zika (ZIKV) and dengue (DENV) 
viruses, are susceptible to Sofosbuvir, a clinically approved 
drug against hepatitis C virus (HCV). Moreover, sofosbuvir 
has a safety record on critically ill hepatic patients, 
making it an attractive option. Their data show that YFV 
RNA polymerase uses conserved amino acid resides for 
nucleotide binding to dock sofosbuvir. This drug inhibited 
YFV replication in different lineages of human hepatoma 
cells, Huh-7 and HepG2, with EC50 value of 4.8 µM. 
Sofosbuvir protected YFV-infected neonatal Swiss mice 
from mortality and weight loss. Their pre-clinical results 
indicate that sofosbuvir could represent an option against 
YFV24.
Prevention strategies and their effectiveness
The live, attenuated yellow fever vaccine was 
developed in 1936 and although there are two main 
substrates that are used in commercial manufacturing 
(17D and 17DD), there appears to be no major differences 
in safety or immunogenicity between them25. The yellow 
fever vaccine provides effective immunity within 30 days 
for 99% of patients15.
Vaccination given to patients aged 9 months and 
older is safe, affordable, and the most effective way to 
prevent yellow fever. World Health Organization (WHO) 
recommends a single dose for most travelers, but those who 
are pregnant during vaccination, had a stem cell transplant, 
plan to spend an extended period in endemic areas or work 
regularly in labs with yellow fever samples may consider 
a booster immunization15.
In April 2013, the World Health Organization 
Strategic Advisory Group of Experts on Immunization 
concluded that a single primary dose of yellow fever 
vaccine is sufficient to confer sustained immunity and 
lifelong protection against yellow fever disease, and that a 
booster dose is not needed26. This conclusion was based on 
a systematic review of published studies on the duration of 
immunity after a single dose of yellow fever vaccine, and 
on data that suggest vaccine failures are extremely rare and 
do not increase in frequency with time since vaccination27.
Although the effectiveness of YF vaccine in humans 
has not been formally tested in controlled clinical trials, 
several observations attest to its effectiveness. Most studies 
showed a consistently high immunogenic response to YF 
vaccine. Four studies evaluated vaccine performance in the 
context of mass vaccination campaigns. The seroconversion 
rates in these studies ranged from 89.7% to 98.2%27. 
Moreover, Tavares-Neto et al.28 reported a seroconversion 
rate of 94% after a vaccination campaign in a remote region 
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of Brazil, which was characterized by its difficult access, 
minimally trained personnel, and limited resources. These 
findings, although not absolute, suggest that YF vaccine is 
effective even in precarious field conditions.
Thirteen observat ional  s tudies provided 
immunogenicity data on 1,137 persons vaccinated more 
than 10 years previously. Using a random effects model, 
the estimated seropositivity rate for persons vaccinated 
more than 10 years previously was 92%. Of the 164 
persons vaccinated ≥20 years previously, the estimated 
seropositivity rate was 80%26.
The recommended immunizing dose of yellow fever 
vaccine is 1000 IU. However, doses as low as 600 IU have 
been shown to induce equivalent levels of neutralizing 
antibodies in 97% of recipients. Potency in routine vaccine 
batches ranges from 1995 IU to 2511886 IU, therefore 
administration of a fraction of the full dose could suffice 
to confer protection in most instances. With this dose-
sparing strategy, a larger proportion of the population at 
risk could be vaccinated in emergency situations when 
vaccine supplies are insufficient. This policy is supported 
by two vaccine trials that demonstrated equal safety and 
immunological non-inferiority. Martins et al. found that 
de-escalation of 17DD-YF vaccine dose from 247 476 
IU to 587 IU resulted in similar seroconversion rates 
and geometric mean titres of neutralizing antibodies in 
military conscripts up to 10 months after subcutaneous (SC) 
vaccination. Visser and Roukens29 showed that intradermal 
administration of a five-fold fractional dose of 17D-204-
YF vaccine was equally immunogenic compared to the SC 
administered standard dose 1 year later.
The vaccine is very well tolerated; in practice 
few patients complain of side effects. In clinical trials, 
where symptoms have been solicited, common adverse 
events include injection site pain or redness, headache, 
malaise, and myalgia within a few days of vaccination in 
approximately 20-25% of vaccines. These symptoms are 
mild and do not interfere with activities. Serious adverse 
reactions to the 17D vaccine are very rare events; they 
include two syndromes, known as yellow fever vaccine-
associated neurotropic disease (YEL-AND) and yellow 
fever vaccine-associated viscerotropic disease (YEL-
AVD)7.
However, it is important to note that the vaccine is 
contraindicated in breastfeeding women due to the potential 
for transmission of vaccine virus via breastmilk. It is also 
contraindicated in infants under age 9 months because of 
the increased risk of encephalitis. Patients with a severe, 
life-threatening allergy to eggs, chicken protein, gelatin, or 
previous yellow fever vaccines should receive the vaccine. 
Extreme caution should be taken before administering the 
vaccine to patients on chemotherapy, with HIV infection, or 
any other condition that compromises the immune system15.
Current situation in Brazil
Yellow fever tends to have a cyclical pattern in 
forested or rural areas of South America, alternating 
between endemic and epidemic periods every 3-7 years, 
reflecting the cyclical epizootics in non-human primates, 
such as monkeys30,31. The last outbreak of yellow fever 
in human primates in Brazil occurred between July 2016 
and June 2017, resulting in 779 confirmed human cases of 
yellow fever and 262 deaths32. However, in 2008-2009, an 
outbreak of yellow fever reporting 56 deaths of non-human 
primates in southeast São Paulo, highlights the significance 
of surveillance and monitoring of epizootic events as an 
early indicator of viral circulation43,44.
Since January 2017, there has been 629 confirmed 
cases of yellow fever in Brazil, including 232 confirmed 
deaths45. As reported by WHO, there has been a tripling 
of confirmed cases of yellow fever in Brazil, particularly 
in São Paulo and Minas Gerais34. This includes 183 
confirmed cases, including 46 deaths in São Paulo, 157 
confirmed cases, including 44 deaths in Minas Gerais, 68 
confirmed cases, including 27 deaths in Rio de Janeiro, and 
1 death in the Federal district33. The suspected source of 
infection of all these cases are from non-human primates, 
with 2242 suspected epizootics in non-human primates, 
411 confirmed between 1 July 2017 and 8 January 201835. 
In December 2017, infected non-human primates were 
reported in urban parks in Greater São Paulo, resulting in 
closure of several parks36. This poses high risks for spread 
of yellow fever through Greater São Paulo, particularly with 
road developments such as a highway traversing through 
the Cantareira mountain region, dense in flora and fauna 
and through densely populated regions of São Paulo and 
Guarulhos, which would facilitate avenues for the infection 
to spread from primates to metropolitan areas42.
On 15 February 2018, yellow fever virus was 
detected in Aedes albopictus mosquitoes for the first time 
in Brazil, found in rural areas of the Ituêta and Alvarenga, 
of Minas Gerais33. This strongly suggests that A. albopictus 
and possibly other species of mosquitos are becoming 
susceptible to yellow fever in not only forested areas, but 
also in areas closely surrounding urban Brazilian cities, 
posing a risk of re-urbanization of the disease41.
Following the recent outbreak of yellow fever in 
Brazil, there are major concerns of re-development of the 
disease in Brazil and factors that may increase risks of 
yellow fever resurfacing in future must be addressed. The 
increasing number of domestic and international tourists 
that visit forest areas may increase risk of transmission and 
dissemination of yellow fever, if these wildlife areas were 
to become infected. Poor vaccination coverage in areas 
of Brazil also leaves large populations to be susceptible 
to the disease, posing high threats to future outbreaks. 
Furthermore, the geographical proximity of forest and 
urban areas in areas of Brazil, as well as large populations 
of monkeys and other non-human primates that occupy 
these areas aid in viral circulation and dissemination of 
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yellow fever. These factors need to be addressed in order 
to not only control the current situation, but also prevent 
future outbreaks from arising41. 
Current response and management
In response to the recent surge in cases of yellow 
fever in Brazil, the Brazilian Ministry of Health initiated 
a mass vaccination campaign of both standard (0.5 mL) 
and fractional (0.1mL) doses, commencing in São Paulo 
and Rio de Janeiro from 25 January to 17 February and 
in Bahia from 19 February to 3 March (32). As of 15 
February 2018, 3.95 million people across São Paulo and 
Rio de Janeiro have been vaccinated; 19.3% of the targeted 
total. Due to the low numbers that were vaccinated, Rio de 
Janeiro authorities extended the duration of its vaccination 
campaign and likewise, São Paulo is assessing the 
potential for extension of its campaign to increase numbers 
vaccinated33. The Ministry of Health aims to vaccinate 21.8 
million people across the three states by the end of the 
vaccination campaign34. On 20 March 2018, vaccination 
campaign was expanded to a nationwide campaign, aiming 
to vaccinate 78 million people by 201943. This decision 
would increase vaccination coverage in Brazil with the 
future challenge to potentially universalize the vaccine 
across not only Brazil, but to every country internationally, 
in order to control yellow fever. However, a major barrier 
to mass vaccination is the shortage of vaccines44.
In response to recent outbreaks, WHO has also 
extended the geographical areas of Brazil for which yellow 
fever vaccinations are required for international travelers 
travelling to Brazil, including all of Espirito Santo, Rio 
de Janeiro, São Paulo and selected areas of Bahia State37. 
WHO recommendations are that all unvaccinated travelers 
aged between nine months and 60 years of age without 
contraindications should be vaccinated for yellow fever at 
least 10 days prior to travelling to at risk areas (Figure 2). 
Advice also include adopting suitable measures to avoid 
mosquito bites, being well-informed of symptoms and signs 
of yellow fever and seeking medical help when recognizing 
these symptoms upon return38.
Figure 2. Expanded yellow fever vaccine recommendation areas in Brazil. Accessed from CDC39
Challenges and approach 
Currently, of major concern to health authorities 
in Brazil and internationally is the large population of 
unvaccinated people in Brazil living in areas considered 
favorable for transmission of yellow fever34. Whilst the 
mass vaccination campaign launched by the Ministry 
of Health aims to combat this issue, the vast areas and 
large population that must be covered in order to ensure 
widespread vaccination coverage remains a great challenge. 
Due to limitations in availability of vaccines, Pan American 
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Health Organization (PAHO) in association with WHO 
recommends that national authorities assess vaccination 
coverage in at risk areas to ensure at least 95% coverage. 
States that are not experiencing outbreaks should not 
conduct vaccination campaigns, to give priority to at risk 
areas. Routine vaccination in children residing in non-
endemic areas should also be postponed to ensure that 
endemic areas are prioritized33.
A confirmed case of yellow fever in an unvaccinated 
returning traveler from Brazil to the Netherlands was 
reported on 11 January 201834. This reinforces the 
importance of vaccination in international travelers to 
Brazil, as it poses the risk of disseminating yellow fever 
to other countries that are receptive to yellow fever, 
such as countries with high prevalence of mosquitoes. 
Consequently, a large area to target is immunization 
requirements for foreign travelers, with proof of yellow 
fever vaccination certificates required upon return from 
affected areas. Particularly with the Carnival occurring 
between 9 and 14 February in Brazil, precautions must 
be taken to prevent the number of unvaccinated travelers 
coming into Brazil for this event39.
The approach to this recent yellow fever outbreak 
should be a holistic movement, involving liaison 
between state, national and international authorities and 
organizations to ensure that the outbreak is contained and 
morbidity and mortality is minimized. Support should 
be provided for the Brazilian government, in the form of 
yellow fever vaccine supplies, syringes and vaccination 
cards, as was provided in previous outbreaks by PAHO 
and WHO. Education remains forefront in ensuring that 
all key stakeholders are well-informed. In December 
2017, a workshop was conducted for yellow fever control 
specialists based in Brasilia, organized by PAHO, the 
Global Outbreak Alert and Response Network (GOARN) 
and WHO, aiming to teach strategies for vaccination in an 
outbreak situation40. PAHO also was involved in mosquito 
control and identifying outbreaks in non-human primates, 
to allow for more targeted vaccination campaigns by 
identifying at risk areas.
CONCLUSION
In the context of the recent outbreak of yellow 
fever in Brazil, increased awareness and knowledge of the 
typical presentation, natural progression and prevention 
of the disease is essential to containing the epidemic. 
Further support and education for healthcare providers on 
the diagnosis, management of yellow fever and vaccine 
available can allow for better quality of care to infected 
individuals. An examination of current and future strategies 
to identify the strengths and weaknesses will be helpful in 
addressing current and future outbreaks. 
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